Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial

Therapy-resistant cancer stem cells (CSCs) contribute to the poor clinical outcomes of patients with recurrent glioblastoma (rGBM) who fail standard of care (SOC) therapy. ChemoID is a clinically validated assay for identifying CSC-targeted cytotoxic therapies in solid tumors. In a randomized clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ranjan, Tulika, Sengupta, Soma, Glantz, Michael J., Green, Richard M., Yu, Alexander, Aregawi, Dawit, Chaudhary, Rekha, Chen, Ricky, Zuccarello, Mario, Lu-Emerson, Christine, Moulding, Hugh D., Belman, Neil, Glass, Jon, Mammoser, Aaron, Anderson, Mark, Valluri, Jagan, Marko, Nicholas, Schroeder, Jason, Jubelirer, Steven, Chow, Frances, Claudio, Pier Paolo, Alberico, Anthony M., Lirette, Seth T., Denning, Krista L., Howard, Candace M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213810/
https://www.ncbi.nlm.nih.gov/pubmed/37137304
http://dx.doi.org/10.1016/j.xcrm.2023.101025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213810/
https://www.ncbi.nlm.nih.gov/pubmed/37137304
http://dx.doi.org/10.1016/j.xcrm.2023.101025

Ejemplares similares